Cantargia Overview
- Founded
-
2010
- Status
-
Public
- Employees
-
23
- Stock Symbol
-
CANTA
- Investments
-
1
- Share Price
-
$0.38
- (As of Thursday Closing)
Cantargia General Information
Description
Cantargia AB is engaged in the development of products used in the treatment of cancer. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's first product candidate, CAN04, has also been designed to treat different forms of cancer, with the initial focus on the treatment of non-small cell lung cancer and pancreatic cancer. The CAN10 project covers a disease segment that complements nadunolimab and diversifies Cantargia's project portfolio.
Contact Information
- Scheelevägen 27
- 223 63 Lund
- Sweden
Cantargia Timeline
Cantargia Stock Performance
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.38 | $0.39 | $0.28 - $0.91 | $59.2M | 167M | 934K | -$0.16 |
Cantargia Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | 28,640 | 4,594 | 130,811 | 735,214 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (27,495) | (36,324) | (42,383) | (18,474) |
| Net Income | (27,713) | (36,650) | (42,677) | (18,772) |
| Total Assets | 31,419 | 45,514 | 66,327 | 112,825 |
| Total Debt | 0 | 0 | 0 | 0 |
Cantargia Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Cantargia Patents
Cantargia Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202105933-D0 | Anti-il1rap antibody | Inactive | 26-Apr-2021 | ||
| AU-2021405730-A1 | Anti-il1rap antibody | Pending | 23-Dec-2020 | 00000000000 | |
| CA-3202942-A1 | Anti-il1rap antibody | Pending | 23-Dec-2020 | 00000000000 | |
| US-11479610-B2 | Anti-il1rap antibody | Active | 23-Dec-2020 | 00000000000 | 00 |
| US-20220242950-A1 | Anti-il1rap antibody | Active | 23-Dec-2020 | C07K16/283 |
Cantargia Executive Team (10)
Cantargia Board Members (8)
| Name | Representing | Role | Since |
|---|---|---|---|
| Magnus Persson MD | Self | Chairman & Board Member | 000 0000 |
| Thoas Fioretos Ph.D | Self | Co-Founder, Board Member & Advisor | 000 0000 |
Cantargia Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Cantargia Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Cantargia Investments (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000000 000 | 10-Mar-2020 | 000000000 | Buildings and Property |
Cantargia ESG
Risk Overview
Risk Rating
Updated April, 01, 2023
35.07 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,491
Rank
Percentile
Pharmaceuticals
Industry
00 of 871
Rank
Percentile
Pharmaceuticals
Subindustry
00 of 415
Rank
Percentile
